People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DiCE MOLECULES HOLDINGS, LLC | — | Other Technology | Series C | $158.8M | $1.3B | 2020 |
| Cedilla Therapeutics, Inc. | — | Biotechnology | Series C | $82.6M | $3.1B | 2020 |
| Septerna, Inc. | — | Biotechnology | Series C | $73.5M | $962.7M | 2023 |
| Vivace Therapeutics, Inc. | — | Biotechnology | Series B | $60.5M | $93.8M | 2025 |
| Outpace Bio, Inc. | — | Biotechnology | Series C | $56.0M | $490.8M | 2024 |
| Convergent Therapeutics, Inc. | — | Biotechnology | Series B | $51.4M | $152.9M | 2023 |
Jake Simson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jake Simson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tim Shannon | 1 | 9 |
| Michael Rubin | 1 | 8 |
| ABBIE CELNIKER | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Vasudev Bailey | 1 | 5 |
| NEIL EXTER | 1 | 5 |
| Alan Ezekowitz | 1 | 4 |
| Shaan Gandhi | 1 | 4 |
| Abraham Bassan | 1 | 4 |
| Sharon Tetlow | 1 | 4 |
| Richard Scheller | 1 | 4 |
| Alexandra Glucksmann | 1 | 4 |
| Kevin Judice | 1 | 3 |
| Tal Zaks | 1 | 3 |
| Bahija Jallal | 1 | 3 |
| Leonard Post | 1 | 3 |
| Eric Sullivan | 1 | 3 |
| Chris Bowden | 1 | 3 |
| Scott Robertson | 1 | 3 |
| Alexander Brown | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.